Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)
Michelle Petri, Ian N Bruce, Thomas Dörner, Yoshiya Tanaka, Eric F. Morand, Kenneth Kalunian, Mario H. Cardiel, Maria Silk, Christina Dickson, Gabriella Meszaros, Lu Zhang, Bochao Jia, Youna Zhao, Conor J McVeigh, Marta Mosca
Topics & Concepts
MedicinePlaceboRheumatoid arthritisClinical endpointInternal medicinePopulationLupus erythematosusAdverse effectSystemic lupus erythematosusClinical trialImmunologyDiseaseAntibodyEnvironmental healthAlternative medicinePathologyRheumatoid Arthritis Research and TherapiesSystemic Lupus Erythematosus ResearchSpondyloarthritis Studies and Treatments